Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)
Status:
Terminated
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The main objective of this project is to demonstrate the feasability of an endomicroscopic
biomarker of efficacy of vedolizumab and adalimumab, in Ulcerative colitis (UC) by coupling
vedolizumab to a fluorescent component, FITC (Fluorescein isothiocyanate) , and adalimumab to
rhodamine.
This project should allow the development of a biomarker of therapeutic efficacy for
vedolizumab and adalimumab that can be used in a single time-frame in vivo in humans, while
respecting manufacturing standards and Good manufacturing procedures.
Phase:
N/A
Details
Lead Sponsor:
Nantes University Hospital
Collaborators:
Institut National de la Santé Et de la Recherche Médicale, France Mauna Kea Technologies Takeda